Vitakine Platelet Cell Therapy from Bioparadox Improves Cardiac Function after Heart Attack, Stanford University Medical Center Study
4/8/2011 7:37:36 AM
EurekAlert! -- Menlo Park, Calif.—April 7, 2011—BioParadox, Inc., a regenerative medicine company pioneering point-of-care biologic treatments for cardiovascular disease, today announced data supporting the use of VitaKine® Platelet Cell Therapy (PCT) as a promising treatment for heart attack patients. The results of a preclinical cardiac study were presented at the 2nd Annual Translational Regenerative Medicine Forum in Washington, D.C.
comments powered by